NEW YORK (GenomeWeb News) – The average CEO compensation at publicly traded omics tools and molecular diagnostics firms rose nearly 7 percent year over year in 2012, according to documents filed with the US Securities and Exchange Commission.

Based on proxy statements filed by 28 of the 29 firms in the GenomeWeb Daily News Index, CEO compensation for 2012 averaged more than $4.8 million, up from a little less than $4.5 million in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.